Neurohypophyseal Diabetes Insipidus
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Neurohypophyseal Diabetes Insipidus

What is the definition of Neurohypophyseal Diabetes Insipidus?

Arginine vasopressin deficiency (previously called neurohypophyseal diabetes insipidus) is a disorder of water balance. The body normally balances fluid intake by releasing fluid in urine. However, people with arginine vasopressin deficiency produce an excessive amount of urine (polyuria), which depletes the amount of water in the body. This water loss also leads to excessive thirst (polydipsia).

What are the causes of Neurohypophyseal Diabetes Insipidus?

The familial form of arginine vasopressin deficiency is caused by variants (also called mutations) in the AVP gene. This gene provides instructions for making a hormone called arginine vasopressin (AVP), which is sometimes also called antidiuretic hormone (ADH). This hormone, which is produced and stored in the brain, helps control the body's water balance.

How prevalent is Neurohypophyseal Diabetes Insipidus?

Arginine vasopressin deficiency occurs in approximately 1 in 25,000 individuals. The acquired form is much more common than the familial form.

Is Neurohypophyseal Diabetes Insipidus an inherited disorder?

Familial arginine vasopressin deficiency is almost always inherited in an autosomal dominant pattern, which means that one copy of the altered AVP gene in each cell is sufficient to cause the disorder.

Who are the top Neurohypophyseal Diabetes Insipidus Local Doctors?
Distinguished in Neurohypophyseal Diabetes Insipidus
Endocrinology | Internal Medicine
Distinguished in Neurohypophyseal Diabetes Insipidus
Endocrinology | Internal Medicine

Reading Hospital Endocrinology & Diabetes Center Wyomissing

1001 Reed Ave, Ste 402, 
Wyomissing, PA 
Languages Spoken:
English

. Dr. Gabriely is rated as a Distinguished provider by MediFind in the treatment of Neurohypophyseal Diabetes Insipidus. He is also highly rated in 59 other conditions, according to our data. His clinical expertise encompasses Low Blood Sugar, Hyperparathyroidism, Thyroid Cancer, and Anaplastic Thyroid Cancer. Dr. Gabriely is board certified in American Board Of Internal Medicine.

Advanced in Neurohypophyseal Diabetes Insipidus
Advanced in Neurohypophyseal Diabetes Insipidus

Diabetes And Endocrinology Center At Specialty Services Pavilion

4350 Emile St., 
Omaha, NE 
Experience:
36+ years
Languages Spoken:
English

Andjela Drincic is an Endocrinologist practicing medicine in Omaha, Nebraska. She has been practicing medicine for over 36 years. Dr. Drincic is rated as an Advanced provider by MediFind in the treatment of Neurohypophyseal Diabetes Insipidus. She is also highly rated in 30 other conditions, according to our data. Her clinical expertise encompasses Type 1 Diabetes (T1D), Pituitary Tumor, Hypogonadism, and Type 2 Diabetes (T2D).

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neurohypophyseal Diabetes Insipidus
Elite in Neurohypophyseal Diabetes Insipidus
Basel, BS, CH 

Mirjam Crain-Christ practices practicing medicine in Basel, Switzerland. Crain-Christ is rated as an Elite expert by MediFind in the treatment of Neurohypophyseal Diabetes Insipidus. They are also highly rated in 14 other conditions, according to our data. Their clinical expertise encompasses Diabetes Insipidus (DI), Neurohypophyseal Diabetes Insipidus, Low Sodium Level, Osmotic Diuresis, and Hormone Replacement Therapy (HRT).

What are the latest Neurohypophyseal Diabetes Insipidus Clinical Trials?
A Study on the Trend of Serum Copeptin Levels and Its Clinical Value for Postoperative Central Diabetes Insipidus in Pediatric Patients After Neurosurgical Intervention in Intensive Care Unit

Summary: Central diabetes insipidus (CDI),a disease caused by the decrease of AVP (a hormone involved in the control of water-electrolyte balance ) secretion and characerized by polyuria, is a common complication after neurosurgerical intervention and there is a lack of diagnostic criteria.Since the surgry casuses damage to patients' AVP-secreting neuronal cells, transient CDI (t-CDI) usually occurs 24-48h...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Oxytocin Substitution Therapy in Patients With AVP Deficiency (Central Diabetes Insipidus)

Summary: This randomized, placebo-controlled, double-blind trial aims to investigate intranasal OXT as a novel therapeutical option in central diabetes insipidus (cDI) to improve psychological symptoms and socio-emotional functioning. Optionally, patients can present for additional assessments in sub-studies: * fMRI sub-study at day 14 (± 2 days) (one additional visit) * Social-stress sub-study at day 14 (...

Who are the sources who wrote this article ?

Published Date: July 19, 2024
Published By: National Institutes of Health